
Approval of AstraZeneca’s Evusheld COVID treatment in Canada is ‘good news,’ experts say
Global News
AstraZeneca Canada said in a press release that its Evusheld has received a Notice of Compliance from Health Canada to treat COVID-19 for those aged 12 or older.
Health Canada has approved AstraZeneca’s antibody combination Evusheld as a treatment for COVID-19, a decision experts say is “good news” that will lead to more treatment options in the future.
AstraZeneca Canada said in a press release Tuesday that its Evusheld, a long-acting antibody combination, has received a Notice of Compliance from Health Canada to treat mild to moderate COVID-19 for those aged 12 or older.
Evusheld was approved in April for the prevention of COVID-19 in immunocompromised people.
According to Health Canada, Evusheld is a monoclonal antibody drug, which will prevent the virus from infecting healthy cells in the body.
“This can help prevent you from getting COVID-19 illness or help your body to overcome the infection and reduce the risk of you developing severe illness,” it reads.
Dr. Zain Chagla, an infectious diseases physician and associate professor at McMaster University, said Evusheld provides a “great option” for immunocompromised patients who are particularly vulnerable to illness from COVID-19.
“There is going to be a lot of different treatments coming down the pipeline and these are really good news,” said Chagla.
He added that there’s still lots of work left to do for implementation and provincial and federal governments must ensure front-line health-care providers have access to COVID-19 treatments for patients.